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Abstract
Background: It is unknown whether there are differences between bacteremia caused by carbapenem resistant
Acinetobacter baumannii (CRAB) and carbapenem resistant Acinetobacter nosocomialis (CRAN). This study aims to
investigate the differences, especially in clinical outcomes, between patients with bacteremia caused by CRAB or CRAN.
Methods: This is a 9-year retrospective study comparing the clinical manifestations, antimicrobial susceptibilities, and
clinical outcomes of 71 patients with CRAB bacteremia and 64 patients with CRAN bacteremia.
Results: Patients with CRAB were more likely to have hematologic malignancies and presented with more shock
episodes than those with CRAN. CRAB isolates were more resistant to various classes of antimicrobials except colistin,
and therefore the patients with CRAB bacteremia were more likely to receive inappropriate antimicrobial therapies. The
14-day mortality was significantly higher in patients with CRAB (40.8% vs. 14.1%; p = 0.001), and in this study,
acquisition of CRAB was identified as an independent risk factor for mortality (odds ratio = 4.003; 95% confidence
interval = 1.566-10.231; p = 0.004).
Conclusions: CRAB and CRAN bacteremia are different in clinical characteristics, antimicrobial susceptibilities, and
mortality rates. Genomic species identification should be performed in the study of carbapenem resistant
Acinetobacters to better delineate the role of different species.
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Background
Acinetobacter species have emerged as important patho-
gens causing nosocomial infections [1]. Carbapenem resist-
ant Acinetobacter spp. are now increasingly encountered
worldwide [2,3], especially in the Asia-Pacific region [4-6].
The three most clinically relevant Acinetobacter species,
Acinetobacter baumannii, Acinetobacter nosocomialis
(formerly Acinetobacter genomic species 13TU), and
Acinetobacter pittii (formerly Acinetobacter genomic spe-
cies 3), cannot be differentiated by phenotypic tests used
in clinical microbiological laboratories and are grouped as
the A. baumannii (Ab) group [1]. Though the prevalence
of Acinetobacter species in the Ab group vary in different
geographic areas and institutions, A. baumannii and A.
nosocomialis are commonly isolated clinical Acinetobacter
species worldwide [7-12] and accounting for more than
80% of clinical infections caused by the Ab group in
Taiwan [10,13,14].
Compared to bacteremia caused by A. nosocomialis,
bacteremia caused by A. baumannii is associated with
worse clinical outcomes [10,12,13,15]. The higher mortal-
ity in patients with A. baumannii might be attributed to a
higher pathogenicity of A. baumannii [10,15]. However, it
is unknown whether the more severe clinical outcomes of
A. baumannii bacteremia compared to A. nosocomialis
bacteremia will be the same if both the pathogens are
carbapenem resistant, as it has been shown that the
virulence of A. baumannii resistant to certain drugs is
impaired [16,17]. In this study, we aim to compare the
clinical characteristics, antimicrobial susceptibilities of the
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bacterial isolates, and especially the clinical outcomes of
patients with bacteremia caused by carbapenem resistant
A. baumannii (CRAB) and A. nosocomialis (CRAN).
Methods
Study population
The study was conducted at the Taipei Veterans General
Hospital (T-VGH) during a nine-year period from January
2000 to December 2008. T-VGH is a 2900-bed tertiary-care
teaching hospital located in Taipei, Taiwan. Data analyses
were performed at the Tri-Service General Hospital
(TSGH), National Defense Medical Center in Taipei,
Taiwan.
Charts were reviewed from all patients with at least one
positive blood culture for A. baumannii or A. nosocomialis
who had symptoms and signs of infection. Only the first
blood culture from patients with two or more positive
blood cultures was included. The source of infection was
determined as recommended in Centers of Disease Con-
trol guidelines [18,19]. Bacteremia cases without a definite
identified source were defined as primary bacteremia.
Patients under 18 years of age and those with incomplete
medical records were excluded. The protocol was approved
by the T-VGH and TSGH Institutional Review Board
(approval number: 2011-10-012IC and 2-101-05-074, re-
spectively) with a waiver for informed consent.
Microbiological studies
The presumptive identification of the isolates to the level of
the Ab group was performed with the API ID 32GN system
(bioMérieux, Marcy l’Etoile, France) or Vitek 2 system
(bioMérieux, Marcy l’Etoile, France). A multiplex-PCR
method was used to identify A. baumannii to the genomic
species level [20]. Isolates identified as non-A. baumannii
species of Acinetobacter were identified to the genomic
species level by 16S–23S ribosomal DNA intergenic spacer
sequence analysis [21]. Antimicrobial susceptibilities were
determined by the agar dilution method according to the
Clinical Laboratory Standards Institute (CLSI) [22]. Multi-
drug resistance was defined as resistance to three or more
of the following classes of antimicrobial agents: anti-
pseudomonal cephalosporins, anti-pseudomonal carba-
penems, ampicillin/sulbactam, fluoroquinolones, and
aminoglycosides [1].
Molecular typing
The clonal relationships of the clinical isolates were deter-
mined by pulsed-field gel electrophoresis (PFGE) [23].
Twenty randomly selected isolates from eachAcinetobacter
species were performed. PFGE of ApaI-digested genomic
DNA was performed using the Bio-Rad CHEF-Mapper
apparatus (Bio-Rad Laboratories, Hercules, CA, USA).
Cluster analysis was performed using BioNumerics version
5.0 (Applied Maths, Sint-Martens-Latem, Belgium) and the
unweighted pair-group method with arithmetic averages
(UPGMA). The Dice correlation coefficient was used with a
tolerance of 1% in order to analyze any similarities between
banding patterns. Isolates showing more than three DNA
fragment differences and a similarity of <80% following
dendrogram analysis were considered to represent different
pulsotypes.
Data collection
Medical records were reviewed to extract clinical informa-
tion, including demographic characteristics, underlying
diseases, duration of stay in an intensive care unit (ICU),
hospital stay, time of receipt, dose and route of adminis-
tration of individual antimicrobials, and the presence of a
ventilator, central venous catheters, a nasogastric tube, or
a foley catheter at the time of onset of bacteremia.
Immunosuppressive therapy was defined as receipt of
cytotoxic agents within 6 weeks, corticosteroids at a dos-
age equivalent to or higher than 10 mg of prednisolone
daily for more than 5 days within 4 weeks, or other im-
munosuppressive agents within 2 weeks prior to the onset
of bacteremia. Neutropenia was defined as an absolute
neutrophil count <0.5×109 neutrophils/L. Recent surgery
was defined as operations performed within 4 weeks prior
to the onset of bacteremia. Chronic kidney disease
was defined as an estimated glomerular filtration rate
<60 mL/min/1.73 m2. Shock was defined as hypotension
(systolic blood pressure [SBP] <90 mmHg, mean arterial
pressure <70mmHg, or a SBP decrease >40 mmHg) with
evidence of end organ dysfunction [24]. Polymicrobial
bacteremia was defined as isolation of one or more mi-
croorganisms other than A. baumannii or A. nosocomialis
from blood during the same bacteremic episode. The se-
verity of illness was evaluated using the Acute Physiology
and Chronic Health Evaluation II (APACHE II) score [25]
within 24 hours prior to bacteremia onset.
Appropriate antimicrobial therapy was defined as ad-
ministration of at least one antimicrobial agent, to which
the causative pathogen was susceptible, within 48 hours
after the onset of bacteremia, with an approved route
and dosage for end organ(s) function. Antimicrobial the-
rapy that did not meet this definition was considered
inappropriate. Monotherapy with an aminoglycoside was
not considered an appropriate therapy. The primary out-
come measure was all-cause 14-day mortality following
the onset of CRAB or CRAN bacteremia.
Statistical analysis
To assess differences, the chi-square test with Yate’s cor-
rection or Fisher’s exact test was used to compare the
discrete variables, while the Student’s t-test or Mann–
Whitney rank sum test was used to analyze continuous
variables. Logistic regression models were used to explore
independent risk factors for 14-day mortality. Univariate
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analyses were performed separately for each of the risk
factor variables to ascertain the odds ratio (OR) and 95%
confidence interval (CI). All biologically plausible variables
with a p value of ≤0.10 in the univariate analysis exhibited
by at least 10% of the patients were considered for inclu-
sion in the logistic regression model for the multivariate
analysis. A backward selection process was utilized. Time
to mortality was analyzed using Kaplan-Meier survival
analysis and long-rank test. A p value <0.05 was con-
sidered statistically significant. All the analyses were
processed with Statistical Package for the Social Sciences
(SPSS) software version 18.0 (SPSS, Chicago, IL, USA).
Results
During the study period, 801 patients were found to have
at least one episode of Ab group bacteremia. Among
them, 185 (23.1%) patients with polymicrobial bacteremia
were excluded from the study. Following genomic species
analysis, 259 (42.0%) and 294 (47.7%) patients were identi-
fied as having bacteremia caused by A. baumannii and A.
nosocomialis, respectively. The final population that met
the entry criteria for this study consisted of 71 patients
with CRAB bacteremia and 64 patients with CRAN
bacteremia. A total of 43 patients were excluded due to
young age (13 patients <18 years) and incomplete medical
records (30 patients).
Among the 20 randomly selected CRAB and CRAN
isolates, the analysis of PFGE showed that there were 7
and 14 pulsotypes, respectively (data not shown).
The demographic and clinical characteristics of the pa-
tients included in the study are summarized in Table 1. The
most common source of CRAB and CRAN bacteremia was
the respiratory tract (66.2% and 70.3%, respectively). Pa-
tients with CRAB had hematologic malignancies more fre-
quently than those with CRAN (12.7% vs. 1.6%, p = 0.019).
Though APACHE II scores at the onset of bacteremia were
similar in both groups, shock was more frequently present
in patients with CRAB.
Table 1 Demographic and clinical characteristics of
patients with bacteremia caused by carbapenem resistant









n (% or interquartile range)
Age in years 75(61.0–82.0) 76(62.0–81.0) 0.78
Gender, male 54(76.1) 46(71.9) 0.7





Respiratory tract 47(66.2) 45(70.3) 0.71
Intravenous device 4(5.6) 7(10.9) 0.35
Intra-abdomen 6(8.5) 3(4.7) 0.5
Wound 2(2.8) 1(1.6) 1
Primary bacteremia 12(16.9) 8(12.5) 0.32
Comorbidity
Coronary artery disease 7(9.9) 11(17.2) 0.31
Congestive heart failure 5(7.0) 11(15.6) 0.11
Cerebral vascular disease 13(18.3) 17(26.6) 0.3
Hypertension 22(31.0) 25(39.1) 0.37
COPD 14(19.7) 20(31.2) 0.17
Alcoholism 7(9.9) 1(1.6) 0.07
Liver cirrhosis 3(4.2) 3(4.7) 1
Diabetes mellitus 20(28.2) 22(34.4) 0.46




Neutropenia 2(2.8) 1(1.6) 1




Solid malignancy 20(28.2) 23(35.9) 0.36
Recent surgery 26(36.6) 29(45.3) 0.38
Trauma 2(2.8) 2(3.1) 1
Procedure†
Abdominal drain 7(9.9) 9(14.1) 0.6
Central venous catheter 49(69.0) 47(73.4) 0.7
Foley catheter 53(74.6) 44(48.8) 0.57
Hemodialysis 9(12.7) 8(12.5) 1
Thoracic drain 1(1.4) 4(6.2) 0.19




Ventilator 49(69.0) 45(70.3) 1
Arterial line 22(31.0) 12(18.8) 0.12
Nasogastric tube 61(85.9) 51(79.7) 0.37
APACHE II score† 26(19.0–34.0) 26(18.3–31.8) 0.1
Table 1 Demographic and clinical characteristics of
patients with bacteremia caused by carbapenem resistant
Acinetobacter baumannii and carbapenem resistant
Acinetobacter nosocomialis* (Continued)




Mortality 43(60.6) 21(32.8) 0.002
14-day mortality 29(40.8) 9(14.1) 0.001
28-day mortality 34(47.9) 13(20.3) 0.001
Time to mortality, day 7(2.0–26.0) 21(9.5–68.5) 0.022
*Data are median value (interquartile range) for continuous variables and
number of cases (%) for categorical variables. †Within 24 hours prior to
bacteremia onset. APACHE II Acute Physiologic and Chronic Health Evaluation
II, COPD chronic obstructive pulmonary disease, ICU intensive care units.
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The antimicrobial susceptibilities of the clinical isolates
of CRAB and CRAN are shown in Table 2. CRAB exhibited
significantly higher rates of resistance to all antimicrobials
tested, except colistin and piperacillin/tazobactam. Only
one A. baumannii isolate was resistant to colistin (1.4%),
while in contrast, 45.3% (29/64) of the A. nosocomialis iso-
lates were resistant to colistin (p<0.001). Clinical isolates of
CRAB exhibited multidrug resistance more frequently than
CRAN (100% vs. 75%, p<0.001). Patients with CRAB more
frequently received inappropriate antimicrobial therapies
than those with CRAN (Table 1).
The antimicrobials used, the APACHE II score, appro-
priateness of antimicrobial use, and patient outcomes are
shown in Table 3. Due to the limited number of cases, dif-
ferences in illness severity, and appropriateness of therapy
in each therapy group, it was difficult to evaluate the effect
of different antimicrobial therapies on patients with CRAB
and CRAN bacteremia. Overall, the mortality rate of
CRAB was higher than CRAN in different antimicrobial
therapy groups. For example, in the carbapenem therapy
groups, in which the illness of severity was comparable
Table 2 Comparison of antimicrobial susceptibilities of
clinical isolates of carbapenem resistant Acinetobacter
baumannii and carbapenem resistant Acinetobacter
nosocomialis
Resistance, n (%)





Amikacin 68(95.8) 30(46.9) <0.001
Gentamicin 68(95.8) 54(84.4) 0.038
Ceftazidime 69(97.2) 14(21.9) <0.001
Cefepime or cefpirome 49(69.0) 13(20.3) <0.001
Ampicillin/sulbactam 43(60.6) 27(42.2) 0.039
Piperacillin/tazobactam 56(78.9) 42(65.6) 0.12
Ciprofloxacin 69(97.2) 4(6.2) <0.001
Colistin 1(1.4) 29(45.3) <0.001
Tigecycline 6(8.2) 0(0) 0.03
Table 3 Antimicrobials used for the patients with carbapenem resistant Acinetobacter baumannii and Acinetobacter
nosocomialis bacteremia*
Main agents used No. of patients APACHE II score No. (%) of patients
Median (interquartile range) Appropriate antimicrobial therapy 14–day mortality
Anti-pseudomonal penicillinsa
CRAB 12 31.5(22.8–39.0) 2(16.7) 6(50.0)
CRAN 8 24(19.0–33.0) 7(87.5) 2(25.0)
Anti-pseudomonal cephalosporinsb
CRAB 14 26(22.8–34.0) 2(14.3) 4(28.6)
CRAN 10 26(19.3–30.0) 7(70.0) 1(10.0)
Anti-pseudomonal fluoroquinolonesc
CRAB 5 30(21.0–36.0) 1(20.0) 2(40.0)
CRAN 2 37.5(37.0–38.0) 2(100.0) 0(0)
Anti-pseudomonal carbapenemsd
CRAB 17 32(24.0–38.5) 0(0) 7(41.2)
CRAN 14 30.5(23.0–33.3) 0(0) 2(14.3)
Ampicillin/sulbactam or sulbactam
CRAB 11 17(15.0–33.0) 4(36.4) 5(45.5)
CRAN 8 24(18.0–27.5) 3(37.5) 0(0)
Non-antipseudomonal β-lactamasese
CRAB 6 17.5(15.3–25.3) 0(0) 1(16.7)
CRAN 9 18(15.5–24.0) 3(33.3) 1(11.1)
Miscellaneous
CRAB 6 25(17.8–32.0) 0(0) 2(33.3)
CRAN 13 27(16.0–35.5) 0(0) 3(23.1)
*Data are median value (interquartile range) for continuous variables and number of cases (%) for categorical variables. aIncluding piperacillin, piperacillin/
tazobactam, and ticarcillin/clavulanate. bIncluding cefoperazone, ceftazidime, cefepime, and cefpirome. cIncluding ciprofloxacin and levofloxacin. dIncluding
imipenem and meropenem. eIncluding penicillin, amoxicillin/clavulanate, cefazolin, cefuroxime, cefotaxime, cefmetazole, and flomoxef. APACHE II Acute
Physiologic and Chronic Health Evaluation II, CRAB carbapenem resistant A. baumannii, CRAN carbapenem resistant A. nosocomialis.
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between both groups, the 14-day mortality rates in CRAB
and CRAN groups were 41.2% vs. 14.3%, respectively. In
the sulbactam therapy group, although the illness severity
was lower in the CRAB group, the 14-day mortality rate
was still higher (45.5 vs. 0%).
The mortality rates by 14 and 28 days after bacteremia
onset were significantly higher in patients with bacteremia
caused by CRAB than CRAN (p = 0.001). The 14-day
mortality for CRAB was 40.8% (29/71) compared with
14.1% (9/64) for CRAN. The average time from admission
to death was significantly shorter in CRAB than CRAN
(16.7 days vs. 39.4 days, p = 0.022). Kaplan-Meier survival
curves reflected the early occurrence of death within a
few days following bacteremia for patients infected with
Figure 1 Kaplan-Meier survival curves for patients with carbapenem resistant Acinetobacter baumannii bacteremia and carbapenem
resistant Acinetobacter nosocomialis bacteremia.
Table 4 Factors associated with 14-day mortality in patients with carbapenem resistant Acinetobacter baumannii and
Acinetobacter nosocomialis bacteremia
Demographic and characteristics Univariate analysis Multivariate analysis
Odds ratio p value Odds ratio p value
(95% CI) (95% CI)
A. baumannii 4.220(1.806–9.861) 0.001 4.003(1.566–10.231) 0.004
APACHE II score* 1.165(1.098–1.237) <0.001
Score ≤25 1.127(0.965–1.317) 0.131
Score >25 1.062(0.986–1.144) 0.113
Score ≤35 1.086(1.012–1.166) 0.022
Score >35 1.056(0.895–1.247) 0.113
Cerebral vascular disease 0.222(0.063–0.783) 0.019 0.194(0.048–0.789) 0.022
Usage of immunosuppressants 4.105(1.827–9.227) 0.001 3.921(1.516–10.143) 0.005
Appropriate antimicrobial therapy 0.381(0.144–1.004) 0.051
Recent surgery 0.190(0.073–0.494) 0.001 0.222(0.079–0.628) 0.005
Shock 2.760(1.244–6.122) 0.013
*Every one increase in APACHE II score is accompanied by an increase of 1.165 in the odds ratio. APACHE II Acute Physiologic and Chronic Health Evaluation II,
CI Confidence interval.
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CRAB. This was followed by higher rates of death in the
CRAB group than the CRAN group (p = 0.001, by log-
rank test) (Figure 1).
Factors associated with 14-day mortality are summa-
rized in Table 4. Bacteremia with CRAB, higher APACHE
II score, use of immunosuppressants and shock were
univariable risk factors for mortality. Following logistic re-
gression analysis, A. baumannii itself was found to be an
independent risk factor for mortality among all patients
(odds ratio = 4.003; 95% confidence interval = 1.566-
10.231; p = 0.004). The usage of immunosuppressants was
also an independent risk factor for mortality.
Discussion
This study clearly demonstrates significant differences in
the risk factors, antimicrobial resistances, and especially
clinical outcomes between bacteremia caused by CRAB
and CRAN. Patients infected with CRAB were more
likely to have hematologic malignancies and a greater
frequency of shock. Even though both pathogens were
carbapenem resistant, CRAB exhibited resistance to
more antimicrobial agents. CRAB bacteremia was also
associated with more frequent instances of inappropriate
antimicrobial use, as well as more rapid and higher mor-
tality rates. Among the patients with CRAB and CRAN
bacteremia, acquisition of CRAB was found to be an in-
dependent factor for 14-day mortality.
Compared with CRAN, CRAB had higher resistance rates
toward most commonly used antimicrobial agents, and all
CRAB isolates were multidrug resistant. This resistance is
responsible for the increased chance of receiving an in-
appropriate antimicrobial therapy in patients infected with
these microorganisms. On the contrary, there were still
some therapeutic options available for the treatment of
CRAN bloodstream infections. A higher rate of colistin
resistance in A. nosocomialis than A. baumannii was also
observed in previous reports [14,26,27], where the resist-
ance of colistin in A. nosocomialis was about 20%. In this
study, it was even higher in CRAN isolates (45.3%).
The higher mortality of patients infected with CRAB
compared to CRAN may be attributed to unfavorable
underlying diseases, an increased likelihood of inappro-
priate antimicrobial therapy in the former group, and
possibly higher pathogenicity of A. baumannii [10,13].
According to our findings, there were more shock epi-
sodes in patients with CRAB than with CRAN of similar
disease severity. Furthermore, CRAB was identified as
an independent risk factor for mortality after adjustment
for other risk factors for mortality, including underlying
diseases, severity of illness, and appropriateness of anti-
microbial therapy. This result indicates a possible higher
pathogenicity of CRAB compared to CRAN. Because of
the diversity of the clonality of CRAB and CRAN iso-
lates, we believe that the result is due to species but not
strain effect. Genomic species identification is therefore
important to better delineate the role of different species
of carbapenem resistant Acinetobacters [21,28].
The prevalence of Acinetobacter species in the Ab group
can vary in different geographic areas and institutions. For
example, A. pittii was found to be the predominant species
accounting for clinical infections in Germany during 2005-
2009 [11]. Although A. baumannii and A. nosocomialis ac-
count for more than 80% of clinical infections caused by the
Ab group, their ratio differs among centers in Taiwan
[10,13-15]. Three centers demonstrated a >2:1 relative ratio
of A. baumannii to A. nosocomialis [10,13,15], however, the
ratio has consistently been around 1:1 in our center in re-
cent years [26,29].
This study is subject to several limitations regularly
found in retrospective studies. Several confounding fac-
tors, especially the antimicrobials used during the whole
treatment course, could not be well controlled in both
groups. However, it is not likely that certain antimicro-
bial regimens that might affect clinical outcomes were
used more often in either group as the primary physi-
cians were unaware of the genomic species.
Conclusions
CRAB and CRAN bacteremia are different in clinical char-
acteristics, antimicrobial susceptibilities, and mortality rates.
Genomic species identification should be performed in the
study of carbapenem resistant Acinetobacters to better de-
lineate the role of different species.
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